SEHK:2142Biotechs
HBM Holdings (SEHK:2142) Valuation After Positive HBM9378 Trial Data And New Regulatory And Licensing Progress
HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed reported positive first in human Phase I data for HBM9378, a TSLP targeting antibody, along with new regulatory milestones and an expanded global licensing arrangement.
See our latest analysis for HBM Holdings.
Those trial results appear to have reignited interest in the shares, with a 1 day share price return of 6.22% lifting HBM Holdings to HK$12.64 and adding to a 1 year total shareholder return of 37.69%. The 3 year total...